Risks and benefits of combining immunosuppressives and biological agents in inflammatory bowel disease: is the synergy worth the risk?
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 17698862.
- Also identified by PMC identifier 1954967.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Since the introduction of infliximab to treat Crohn's disease, combination therapy with immunosuppressants has reduced immunogenicity, without impacting efficacy. The availability of novel anti-TNF agents and potential combined toxicities question the risk/benefit of combination therapies.
Medical subject headings
- Immunosuppressive Agents
- Inflammatory Bowel Diseases